Cargando…

Comparative efficacy of vasoactive medications in patients with septic shock: a network meta-analysis of randomized controlled trials

BACKGROUND: Catecholamines, especially norepinephrine, are the most frequently used vasopressors for treating patients with septic shock. During the recent decades, terlipressin, vasopressin V1A agonist, and even Ca(2+) sensitizer were increasingly used by physicians. The aim of this study is to com...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Lu, Yan, Jing, Han, Shutang, Chen, Qiuhua, Chen, Mingqi, Jiang, Hua, Lu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518735/
https://www.ncbi.nlm.nih.gov/pubmed/31088524
http://dx.doi.org/10.1186/s13054-019-2427-4
_version_ 1783418516939997184
author Cheng, Lu
Yan, Jing
Han, Shutang
Chen, Qiuhua
Chen, Mingqi
Jiang, Hua
Lu, Jun
author_facet Cheng, Lu
Yan, Jing
Han, Shutang
Chen, Qiuhua
Chen, Mingqi
Jiang, Hua
Lu, Jun
author_sort Cheng, Lu
collection PubMed
description BACKGROUND: Catecholamines, especially norepinephrine, are the most frequently used vasopressors for treating patients with septic shock. During the recent decades, terlipressin, vasopressin V1A agonist, and even Ca(2+) sensitizer were increasingly used by physicians. The aim of this study is to compare the efficacy of such different kinds of vasoactive medications on mortality among patients with septic shock. METHODS: Relevant randomized controlled trials were identified by searching PubMed, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials updated to February 22, 2018. A network meta-analysis was performed to evaluate the effect of different types of vasoactive medications. The primary outcome was 28-day mortality. Intensive care unit (ICU) mortality, hospital and ICU length of stay (LOS), and adverse events were also assessed. RESULTS: A total of 43 trials with 5767 patients assessing 17 treatment modalities were included. Treatments ranking based on surface under the cumulative ranking curve values from largest to smallest were NE/DB 85.9%, TP 75.1%, NE/EP 74.6%, PI 74.1%, EP 72.5%, VP 66.1%, NE 59.8%, PE 53.0%, DA 42.1%, DX 38.2%, SP 27.0%, PA 24.3%, EX 22.8%, LE 21.5%, and DB 13.3% for 28-day mortality. Treatments ranking for ICU mortality were TP/NE 86.4%, TP 80.3%, TP/DB/NE 65.7%, VP/NE 62.8%, NE 57.4%, VP 56.5%, PE 48.4%, DA 33.0%, PA 27.5%, LE 22.1%, and DB 9.9%. The incidence of myocardial infarction was reported with NE/EP 3.33% (n = 1 of 30), followed by EP 3.11% (n = 5 of 161), and then VP 3.10% (n = 19 of 613), NE 3.03% (n = 43 of 1417), DA 2.21% (n = 19 of 858), NE/DB 2.01% (n = 4 of 199), LE 1.16% (n = 3 of 258), and PA 0.39% (n = 1 of 257). The incidence of arrhythmia was reported with DA 26.01% (n = 258 of 992), followed by EP 22.98% (n = 37 of 161), and then NE/DB 20.60% (n = 41 of 199), NE/EP 20.0% (n = 6 of 30), NE 8.33% (n = 127 of 1525), LE 5.81% (n = 15 of 258), PA 2.33% (n = 6 of 257), and VP 1.67% (n = 10 of 600). CONCLUSIONS: The use of norepinephrine plus dobutamine was associated with lower 28-day mortality for septic shock, especially among patients with lower cardiac output. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13054-019-2427-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6518735
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-65187352019-05-21 Comparative efficacy of vasoactive medications in patients with septic shock: a network meta-analysis of randomized controlled trials Cheng, Lu Yan, Jing Han, Shutang Chen, Qiuhua Chen, Mingqi Jiang, Hua Lu, Jun Crit Care Research BACKGROUND: Catecholamines, especially norepinephrine, are the most frequently used vasopressors for treating patients with septic shock. During the recent decades, terlipressin, vasopressin V1A agonist, and even Ca(2+) sensitizer were increasingly used by physicians. The aim of this study is to compare the efficacy of such different kinds of vasoactive medications on mortality among patients with septic shock. METHODS: Relevant randomized controlled trials were identified by searching PubMed, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials updated to February 22, 2018. A network meta-analysis was performed to evaluate the effect of different types of vasoactive medications. The primary outcome was 28-day mortality. Intensive care unit (ICU) mortality, hospital and ICU length of stay (LOS), and adverse events were also assessed. RESULTS: A total of 43 trials with 5767 patients assessing 17 treatment modalities were included. Treatments ranking based on surface under the cumulative ranking curve values from largest to smallest were NE/DB 85.9%, TP 75.1%, NE/EP 74.6%, PI 74.1%, EP 72.5%, VP 66.1%, NE 59.8%, PE 53.0%, DA 42.1%, DX 38.2%, SP 27.0%, PA 24.3%, EX 22.8%, LE 21.5%, and DB 13.3% for 28-day mortality. Treatments ranking for ICU mortality were TP/NE 86.4%, TP 80.3%, TP/DB/NE 65.7%, VP/NE 62.8%, NE 57.4%, VP 56.5%, PE 48.4%, DA 33.0%, PA 27.5%, LE 22.1%, and DB 9.9%. The incidence of myocardial infarction was reported with NE/EP 3.33% (n = 1 of 30), followed by EP 3.11% (n = 5 of 161), and then VP 3.10% (n = 19 of 613), NE 3.03% (n = 43 of 1417), DA 2.21% (n = 19 of 858), NE/DB 2.01% (n = 4 of 199), LE 1.16% (n = 3 of 258), and PA 0.39% (n = 1 of 257). The incidence of arrhythmia was reported with DA 26.01% (n = 258 of 992), followed by EP 22.98% (n = 37 of 161), and then NE/DB 20.60% (n = 41 of 199), NE/EP 20.0% (n = 6 of 30), NE 8.33% (n = 127 of 1525), LE 5.81% (n = 15 of 258), PA 2.33% (n = 6 of 257), and VP 1.67% (n = 10 of 600). CONCLUSIONS: The use of norepinephrine plus dobutamine was associated with lower 28-day mortality for septic shock, especially among patients with lower cardiac output. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13054-019-2427-4) contains supplementary material, which is available to authorized users. BioMed Central 2019-05-14 /pmc/articles/PMC6518735/ /pubmed/31088524 http://dx.doi.org/10.1186/s13054-019-2427-4 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Cheng, Lu
Yan, Jing
Han, Shutang
Chen, Qiuhua
Chen, Mingqi
Jiang, Hua
Lu, Jun
Comparative efficacy of vasoactive medications in patients with septic shock: a network meta-analysis of randomized controlled trials
title Comparative efficacy of vasoactive medications in patients with septic shock: a network meta-analysis of randomized controlled trials
title_full Comparative efficacy of vasoactive medications in patients with septic shock: a network meta-analysis of randomized controlled trials
title_fullStr Comparative efficacy of vasoactive medications in patients with septic shock: a network meta-analysis of randomized controlled trials
title_full_unstemmed Comparative efficacy of vasoactive medications in patients with septic shock: a network meta-analysis of randomized controlled trials
title_short Comparative efficacy of vasoactive medications in patients with septic shock: a network meta-analysis of randomized controlled trials
title_sort comparative efficacy of vasoactive medications in patients with septic shock: a network meta-analysis of randomized controlled trials
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518735/
https://www.ncbi.nlm.nih.gov/pubmed/31088524
http://dx.doi.org/10.1186/s13054-019-2427-4
work_keys_str_mv AT chenglu comparativeefficacyofvasoactivemedicationsinpatientswithsepticshockanetworkmetaanalysisofrandomizedcontrolledtrials
AT yanjing comparativeefficacyofvasoactivemedicationsinpatientswithsepticshockanetworkmetaanalysisofrandomizedcontrolledtrials
AT hanshutang comparativeefficacyofvasoactivemedicationsinpatientswithsepticshockanetworkmetaanalysisofrandomizedcontrolledtrials
AT chenqiuhua comparativeefficacyofvasoactivemedicationsinpatientswithsepticshockanetworkmetaanalysisofrandomizedcontrolledtrials
AT chenmingqi comparativeefficacyofvasoactivemedicationsinpatientswithsepticshockanetworkmetaanalysisofrandomizedcontrolledtrials
AT jianghua comparativeefficacyofvasoactivemedicationsinpatientswithsepticshockanetworkmetaanalysisofrandomizedcontrolledtrials
AT lujun comparativeefficacyofvasoactivemedicationsinpatientswithsepticshockanetworkmetaanalysisofrandomizedcontrolledtrials